Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Neumora Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-06-15).
- Leadership changes: the latest reported is Paul L. Berns, Chief Executive Officer (Form 8-K filed 2026-08-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Arch Venture Fund Xii, L.P. (filed 2026-04-01).
Who is behind it
Neumora Therapeutics, Inc.: incorporated in Delaware; business address in Watertown, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- Paul Berns: Executive Officer, Director (Form D, 2023-01-03)
- Joshua Pinto: Executive Officer (Form D, 2023-01-03)
- Tamara Tompkins: Executive Officer (Form D, 2023-01-03)
- Stacie Weninger: Director (Form D, 2023-01-03)
- Matthew Fust: Director (Form D, 2023-01-03)
- Robert Nelsen: Director (Form D, 2023-01-03)
- Kari Stefansson: Director (Form D, 2023-01-03)
- Kristina Burow: Director (Form D, 2023-01-03)
- Maykin Ho: Director (Form D, 2023-01-03)
- Alaa Halawa: Director (Form D, 2023-01-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | K2 Healthventures Equity Trust LLC | 3.1% |
| Schedule 13G/A, 2026-05-04 | Raymond Debbane | 4.7% |
| Schedule 13D/A, 2026-04-01 | Arch Venture Fund Xii, L.P. | 18.7% |
| Schedule 13G, 2026-02-19 | Raymond Debbane | 5.4% |
| Schedule 13G/A, 2026-02-17 | K2 Healthventures Equity Trust LLC | 5.01% |
| Schedule 13D/A, 2025-10-29 | Arch Venture Fund Xii, L.P. | 20.7% |
| Schedule 13G, 2025-08-11 | K2 Healthventures Equity Trust LLC | 6.6% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-14 | Paul L. Berns | Chief Executive Officer | appointed | 2026-08-14 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-01-03 | $474.36M | $474.36M |
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-06-15).
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/neumora-therapeuticsLast updated 2026-10-18
Who owns Neumora Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/neumora-therapeutics